Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 10/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | UBE2N | P61088 | 2/20 | 0.67 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.66 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20561098 | 0.87 | LMNA (0.80) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL17750785 | 0.87 | LMNA (0.89) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL1944405 | 0.83 | ADORA2B (1.00) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL20561174 | 0.82 | LMNA (1.00) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL16120984 | 0.81 | ADORA2B (0.81) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL20561099 | 0.81 | LMNA (0.78) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL7018070 | 0.80 | LMNA (0.68) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL19533057 | 0.80 | ADORA2B (0.73) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL17772702 | 0.79 | SMN1; SMN2 (0.74) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 | |
| SCHEMBL15722804 | 0.79 | SMN1; SMN2 (0.73) | ADORA2BSMN1; SMN2RXFP1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240392273-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| EP-3624846-B1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY INCLUDING A COMBINATION OF NICOTINIC ACID AND TRYOPTOPHAN | BHAMIS RES LABORATORY PVT LTD (IN) | 2024-08-07 | — | — | EP | disclosed |
| EP-4401758-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | Takeda Pharmaceutical Company Limited (JP) | 2024-07-24 | — | — | EP | disclosed |
| CN-118139636-A | Delivery of promoted concentrated antibody formulations using hyaluronidase | 武田药品工业株式会社 | 2024-06-04 | — | — | CN | disclosed |
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-11 | — | — | US | disclosed |
| US-11738082-B2 | High concentration protein formulations with reduced viscosity | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2023-08-29 | — | — | US | disclosed |
| WO-2023042096-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | WO | disclosed |
| US-20200254094-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2020-08-13 | — | — | US | disclosed |
| US-10646569-B2 | High concentration protein formulations with reduced viscosity | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2020-05-12 | — | — | US | disclosed |
| EP-3624846-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2020-03-25 | — | — | EP | disclosed |
| US-20180333493-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2018-11-22 | — | — | US | disclosed |
| WO-2018211517-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10646569-B2 | High concentration protein formulations with reduced viscosity | ALB, TTR, MAX | ADORA2B 3824/4885SMN1; SMN2 320/4885RXFP1 1610/4885 |
| US-20200254094-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | ALB, TTR, MAX | ADORA2B 3824/4885SMN1; SMN2 320/4885RXFP1 1610/4885 |
| US-11738082-B2 | High concentration protein formulations with reduced viscosity | ALB, TTR, MAX | ADORA2B 3824/4885SMN1; SMN2 320/4885RXFP1 1610/4885 |
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | ALB, TTR, MAX | ADORA2B 3824/4885SMN1; SMN2 320/4885RXFP1 1610/4885 |
| US-20180333493-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | ALB, TTR, MAX | ADORA2B 3824/4885SMN1; SMN2 320/4885RXFP1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.